Komori
Presentation materials for financial results4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Financial Results Briefing Materials for FY2025 (Fiscal Year Ending March 2026)

FY2025 saw a substantial increase in profit, driven by growth in North American products, sales milestone revenue and the effects of structural reforms. For FY2026, revenue is expected to increase, while core operating profit and net income are expected to decline because the gain on the business transfer recognized in the previous fiscal year will not recur. The reportable segments will also be changed to a single Pharmaceuticals segment.

Worth reading
82Important
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
545
¥100 million (year-on-year increase in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFY2025 (fiscal year ending March 2026)10 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales4,533 Hundreds of millions of yen+13.7%
Operating profit1,073 Hundreds of millions of yen+272.6%
Ordinary income1,003 Hundreds of millions of yen+469.8%
Net income1,069 Hundreds of millions of yen+352.2%
Selling, general and administrative expenses1,593 Hundreds of millions of yen
Full-year earnings forecast
Revenue
5,400 Hundreds of millions of yen
Operating profit
900 Hundreds of millions of yen
Profit for the period attributable to owners of the parent
770 Hundreds of millions of yen
Core operating profit
910 Hundreds of millions of yen
Research and development costs
510 Hundreds of millions of yen
Capital Expenditure and Investments
120 Hundreds of millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in revenue+¥54.5 billion
  • Decrease in SG&A expenses−¥8.4 billion
  • Decrease in R&D expenses-¥4.5 billion
  • Increase in other items within core operating profit+¥38.6 billion
  • Increase in adjustment items+¥15.8 billion
  • Foreign exchange impact on revenue-¥5.3 billion
  • Increase in North American revenue+¥86.1 billion
  • Decrease in Japanese revenue−¥7.5 billion
  • Decrease in Asian revenue−¥24.2 billion
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • FY2026 forecast exchange rateUS$1 = ¥155.00
  • FY2026 forecast revenue5,400 Hundreds of millions of yen
  • FY2026 forecast research and development expenses510 Hundreds of millions of yen
New initiatives
  • Change the reportable segments from 3 geographic segments to a single Pharmaceuticals segment
  • Promote growth investments and structural reforms under Boost 2028
  • Plan to begin the post-marketing clinical trial for アムシェプリ during 2026
  • Begin the Phase 1 trial of DSP-0551
  • Advance clinical development in oncology and universal influenza vaccines
Key KPIsA metric the company considers important as a management benchmark.
  • Orgovyx revenue in the US1,029 USD million
    Year on year against the same period last yearApproximately 89% increase
  • Gemtesa revenue in the US637 USD million
    Year on year against the same period last yearApproximately 48% increase
  • Orgovyx achievement rate against the initial forecast145 %
  • Gemtesa achievement rate against the initial forecast111 %
  • Equity ratio attributable to owners of the parent36.4 %
    Year on year against the same period last yearUp from 22.8%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • ProductOrgovyx
    Number of versionsNearly doubled year on year
    Unit price factorsThe impact of payer mix and coupon utilization were below expectations
  • ProductGemtesa
    Number of versionsGrowth in prescription volume and market share
    Unit price factorsIncreased from the initial forecast due to the impact of payer mix and other factors
Segment results
Japan
Revenue
924 Hundreds of millions of yen
Core segment profit
124 Hundreds of millions of yen
Year on year against the same period last year
Revenue−¥7.5 billion
Core segment profit+¥900 million
North America
Revenue
3,379 Hundreds of millions of yen
Core segment profit
757 Hundreds of millions of yen
Year on year against the same period last year
Revenue+¥86.1 billion
Core segment profit+¥33.1 billion
Asia
Revenue
230 Hundreds of millions of yen
Core segment profit
95 Hundreds of millions of yen
Year on year against the same period last year
Revenue−¥24.2 billion
Core segment profit−¥14.5 billion
Medium-term management plan targets
Boost 2028: further revenue growth for Orgovyx and Gemtesa, the fastest possible launches of 2 oncology products, development of next-generation growth engines and strengthening of the financial base. Specific revenue and other targets: not disclosed
Financial targets
ROE
FY2025 actual46.3%
FY2026 forecast20.3%
ROIC
FY2025 actual22.8%
FY2026 forecast15.1%
Equity ratio
March 202522.8%
March 202636.4%
Capital expenditures
¥120 100 million capital expenditures, investments and loans
Payout ratio
Not disclosed (shareholder returns for FY2026 have not been determined)
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFY2025 (fiscal year ending March 2026)
Net Sales4,533 Hundreds of millions of yen (YoY +13.7%)
Operating profit1,073 Hundreds of millions of yen (YoY +272.6%)
Ordinary income1,003 Hundreds of millions of yen (YoY +469.8%)
Net income1,069 Hundreds of millions of yen (YoY +352.2%)
Selling, general and administrative expenses1,593 Hundreds of millions of yen
Full-year earnings forecastRevenue 5,400 Hundreds of millions of yen / Operating profit 900 Hundreds of millions of yen / Profit for the period attributable to owners of the parent 770 Hundreds of millions of yen / Core operating profit 910 Hundreds of millions of yen / Research and development costs 510 Hundreds of millions of yen / Capital Expenditure and Investments 120 Hundreds of millions of yen
Segment resultsJapan Revenue 924 Hundreds of millions of yen / Core segment profit 124 Hundreds of millions of yen / Year on year against the same period last year Revenue −¥7.5 billion / Core segment profit +¥900 million / North America Revenue 3,379 Hundreds of millions of yen / Core segment profit 757 Hundreds of millions of yen / Year on year against the same period last year Revenue +¥86.1 billion / Core segment profit +¥33.1 billion / Asia Revenue 230 Hundreds of millions of yen / Core segment profit 95 Hundreds of millions of yen / Year on year against the same period last year Revenue −¥24.2 billion / Core segment profit −¥14.5 billion
Breakdown of Factors Affecting the ChangeFactors Increase in revenue / Amount +¥54.5 billion, Factors Decrease in SG&A expenses / Amount −¥8.4 billion, Factors Decrease in R&D expenses / Amount -¥4.5 billion, Factors Increase in other items within core operating profit / Amount +¥38.6 billion, Factors Increase in adjustment items / Amount +¥15.8 billion, Factors Foreign exchange impact on revenue / Amount -¥5.3 billion, Factors Increase in North American revenue / Amount +¥86.1 billion, Factors Decrease in Japanese revenue / Amount −¥7.5 billion, Factors Decrease in Asian revenue / Amount −¥24.2 billion
Key KPIsIndicator name Orgovyx revenue in the US / Value 1,029 USD million / Year on year against the same period last year Approximately 89% increase, Indicator name Gemtesa revenue in the US / Value 637 USD million / Year on year against the same period last year Approximately 48% increase, Indicator name Orgovyx achievement rate against the initial forecast / Value 145 % / Year on year against the same period last year Not disclosed, Indicator name Gemtesa achievement rate against the initial forecast / Value 111 % / Year on year against the same period last year Not disclosed, Indicator name Equity ratio attributable to owners of the parent / Value 36.4 % / Year on year against the same period last year Up from 22.8%
Unit price and quantity metricsProduct Orgovyx / Number of versions Nearly doubled year on year / Unit price factors The impact of payer mix and coupon utilization were below expectations, Product Gemtesa / Number of versions Growth in prescription volume and market share / Unit price factors Increased from the initial forecast due to the impact of payer mix and other factors
Assumptions Underlying the Business OutlookItem FY2026 forecast exchange rate / Value US$1 = ¥155.00, Item FY2026 forecast revenue / Value 5,400 Hundreds of millions of yen, Item FY2026 forecast research and development expenses / Value 510 Hundreds of millions of yen
Medium-term management plan targetsBoost 2028: further revenue growth for Orgovyx and Gemtesa, the fastest possible launches of 2 oncology products, development of next-generation growth engines and strengthening of the financial base. Specific revenue and other targets: not disclosed
Financial targetsROE FY2025 actual 46.3% / FY2026 forecast 20.3% / ROIC FY2025 actual 22.8% / FY2026 forecast 15.1% / Equity ratio March 2025 22.8% / March 2026 36.4%
Payout ratioNot disclosed (shareholder returns for FY2026 have not been determined)
Capital expenditures¥120 100 million (capital expenditures, investments and loans)
New initiativesChange the reportable segments from 3 geographic segments to a single Pharmaceuticals segment, Promote growth investments and structural reforms under Boost 2028, Plan to begin the post-marketing clinical trial for アムシェプリ during 2026, Begin the Phase 1 trial of DSP-0551, Advance clinical development in oncology and universal influenza vaccines
Items this document does not state (13)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Performance improved in FY2025 due to growth in Orgovyx and Gemtesa, sales milestone revenue, the effects of business structure improvements and the partial transfer of the Asia business. For FY2026, growth in Orgovyx and Gemtesa and sales milestone revenue are expected, while the assumptions include the absence of the gain on the partial transfer of the Asia business in the previous fiscal year and the incorporation of a certain level of tariff and inflation risks.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for FY2025 (Fiscal Year Ending March 2026) | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori